Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 286.64m |
Free float | 266.99m |
P/E (TTM) | -- |
Market cap | 2.25bn USD |
EPS (TTM) | -1.53 USD |
--
More ▼
Announcements
- Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
- Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
- Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
- Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
- CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
- Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
More ▼